Terminated PHASE1 INTERVENTIONAL 1-arm NCT06193174

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

A Phase IB (Repeat Dosing) Trial of Second Dose Oncolytic HSV Administered Intratumorally in Patients With Recurrent Malignant Glioma.

Sponsor: University of Alabama at Birmingham

Conditions Anaplastic Astrocytoma of Brain Glioblastoma Multiforme of Brain Gliosarcoma of Brain Recurrent Malignant Glioma

Interventions C134 Re-Administration

Updated 5 times since 2024 Last updated: Jan 20, 2026 Started: Jun 21, 2024 Primary completion: Mar 7, 2025 Completion: Mar 7, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Not enough eligible participants to enroll.

Other terminated trials from University of Alabama at Birmingham

See all terminations from University of Alabama at Birmingham

A PHASE1 clinical study on Anaplastic Astrocytoma of Brain and Glioblastoma Multiforme of Brain, this trial is terminated or withdrawn. The trial is conducted by University of Alabama at Birmingham and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE1

Status: Enrolling By Invitation → Terminated
Feb 2025 — Feb 2026 [monthly]

Enrolling By Invitation PHASE1

Status: Not Yet Recruiting → Enrolling By Invitation
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States